Tango Therapeutics, Inc. Tango Therapeutics, Inc.

Tango Therapeutics, Inc.

TNGX

Ранг среди акций #4542
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and... Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
Цена акции
$27.18
Последняя синхронизация: 2026-07-31
Рыночная капитализация
$3.38B
Изменение (1 день)
-1.41%
Изменение (1 год)
197.05%
Страна
US
Торговля Tango Therapeutics, Inc. (TNGX)

Категория

Healthcare
История дивидендной доходности для Tango Therapeutics, Inc. (TNGX)
Дивидендная доходность (TTM) компании Tango Therapeutics, Inc. (тикер: TNGX) на 2023-12-31 составляет: 0.00%
Средняя дивидендная доходность за последние 5 лет: 0.00%
История дивидендной доходности компании Tango Therapeutics, Inc. (TNGX) с 2019 по 2026
Дивидендная доходность на конец каждого года (TTM)
Год Дивидендная доходность Изменить
2026 (TTM) 0.00% 0.00%
2024 0.00% 0.00%
2023 0.00% 0.00%
2022 0.00% 0.00%
2021 0.00% 0.00%
2020 0.00% 0.00%
2019 0.00% 0.00%
Дивидендная доходность (TTM) аналогичных компаний или конкурентов
Компания Дивидендная доходность Страна
0.00%
US
0.00%
US
2.17%
AU
0.00%
CH
0.00%
NL